Melanoma antigens recognized by T cells and their use for immunotherapy

Abstract

AbstractMelanoma has been a prototype for cancer immunology research, and the mechanisms of anti‐tumor T‐cell responses have been extensively investigated in patients treated with various immunotherapies. Individual differences in cancer‐immune status are defined mainly by cancer cell characteristics such as DNA mutations generating immunogenic neo‐antigens, and oncogene activation causing immunosuppression, but also by patients' genetic backgrounds such as HLA types and genetic polymorphisms of immune related molecules, and environmental and lifestyle factors such as UV rays, smoking, gut microbiota and concomitant medications; these factors have an influence on the efficacy of immunotherapy. Recent comparative studies on responders and non‐responders in immune‐checkpoint inhibitor therapy using various new technologies including multi‐omics analyses on genomic DNA, mRNA, metabolites and microbiota and single cell analyses of various immune cells have led to the advance of human tumor immunology and the development of new immunotherapy. Based on the new findings from these investigations, personalized cancer immunotherapies along with appropriate biomarkers and therapeutic targets are being developed for patients with melanoma. Here, we will discuss one of the essential subjects in tumor immunology: identification of immunogenic tumor antigens and their effective use in various immunotherapies including cancer vaccines and adoptive T‐cell therapy.